Krystal Biotech, Inc. (KRYS): R&D Expense
$58.05M
Year ended 2025-12-31
$59.23M
Trailing 12 months to 2026-06-30
+11.0%
3-year compound annual growth
+26.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $58.05M | +8.3% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $53.58M | +15.4% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $46.43M | +9.4% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $42.46M | +52.3% | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | $27.88M | +55.5% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $17.94M | +14.9% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $15.62M | +101.2% | 2021-03-01, From 2019-01-01 |
| 2018-12-31 | $7.76M | +141.9% | 2020-03-10, From 2018-01-01 |
| 2017-12-31 | $3.21M | +332.9% | 2018-03-12, From 2017-01-01 |
| 2016-12-31 | $741.0K | n/a | 2018-03-12, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $58.05M | +8.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $274.87M | +23.7% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $80.28M | -11.6% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $64.32M | +20.5% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $4.76M | +162.7% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $93.77M | -8.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.56M | +11.2% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $300.27M | +8.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
Compare KRYS, IMCR, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗